Pharmacokinetics of bambuterol in healthy subjects

British Journal of Clinical Pharmacology

Volumn 45, Issue 5, 1998, Pages 471-478

  Nyberg, Lars ^a   Rosenborg, Johan ^a   Weibull, Eva ^a   Jönsson, Sven ^b   Kennedy, Britt Marie ^b   Nilsson, Marita ^a  

^a Human Pharmacology   (Sweden)

^b Astra Draco AB   (Sweden)

Author keywords

Bambuterol; Bioavailability; Pharmacokinetics; Plasma cholinesterase; Terbutaline

Indexed keywords

BAMBUTEROL; CHOLINESTERASE; PRODRUG; TERBUTALINE;

ADULT; ARTICLE; CHOLINESTERASE BLOOD LEVEL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; PULSE RATE; TREMOR; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; CHOLINESTERASES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRODRUGS; TERBUTALINE;

EID: 0031959757     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00695.x     Document Type: Article

References (21)

1. Olsson OAT, Svensson L. New lipophilic terbutaline ester prodrugs with long effect duration. Pharm Res 1984; 3: 19-23.
2. 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem Pharmacol 1988; 37: 3867-3876.
3. Tunek A, Svensson L. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterase in human blood. Drug Metab Dispos 1988; 16: 759-764.
4. Svensson L, Tunek A. The design and bioactivation of presystemically stable prodrugs. Drug Metab Rev 1988; 19: 165-194.
5. Lindberg C, Roos C, Tunek A, Svensson L Å. Metabolism of bambuterol in rat liver microsomes: identification of hydroxylated and demethylated products by liquid chromatography mass spectrometry. Drug Metab Dispos 1989; 17: 311-322.
6. Petrie GR, Chookang JY, Hassan WU, et al. Bambuterol: effective in nocturnal asthma. Respir Med 1993; 87: 581-585.
7. D'Alonzo G, Smolensky M, Feldman S, et al. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. Chest 1995; 107: 406-412.
8. Fugleholm AM, Ibsen TB, Laxmyr L, Svendsen UG. Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. Eur Respir J 1993; 6: 1474-1478.
9. Augustinsson K-B, Eriksson H, Faijersson Y. A new approach to determining cholinesterase activities in samples of whole blood. Clin Chim Acta 1978; 89: 239-252.
10. Steiner E, Iselius L, Alvàn G, et al. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 1985; 38: 394-401.
11. Lindberg C, Jönsson S, Paulson J. Determination of bambuterol, a prodrug of terbutaline, in plasma and urine by gas chromatography mass spectrometry. Biomed Environ Mass Spectrom 1990; 19: 218-224.
12. Kennedy B-M, Blomgren A, Edholm L-E, Roos C. Quantitative determination of terbutaline in human plasma after administration of bambuterol using coupled columns and electrochemical detection. Chromatographia 1987; 24: 895-899.
13. Bengtsson B, Fagerström P-O. Extrapulmonary effects of terbutaline during prolonged administration. Clin Pharmacol Ther 1982; 31: 726-732.
14. Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. In The Pharmacological Basis of Therapeutics, Seventh Edition, eds Goodman Gilman A, Goodman LS, Rall TW, Murad F, New York: Macmillan Publishing Company, 1985: 145-180.
15. Ahrens RC. Skeletal muscle tremor and the influence of adrenergic drugs. J Asthma 1990; 27: 11-20.
16. Nyberg L. Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Resp Dis 1984; 65(suppl.134): 149-160.
17. Rowland M, Tozer T. Mean residence time (Appendix 1). In Clinical Pharmacokinetics, Concepts and Applications, Second Edition, London: Lea and Febiger, 1989: 479-485.
18. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980; 8: 509-534.
19. Rowland M, Tozer T. Extravascular dose. In Clinical Pharmacokinetics, Concepts and Applications, Second Edition, London: Lea & Febiger, 1989: 33-48.
20. Benet LZ. Mean residence time in the body versus mean residence time in the central compartment. J Pharmacokinet Biopharm 1985; 13: 555-558.
21. Hörnblad Y, Ripe E, Magnusson P-O, Tegnér K. The metabolism and clinical activity of terbutaline and its prodrug ibuterol. Eur J Clin Pharmacol 1976; 10: 9-18.